SF116 clone 1

General

Cell Line

hPSCreg name UNEWi026-A
Cite as:
UNEWi026-A (RRID:CVCL_IT97)
Alternative name(s)
SF116 clone 1
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
UNEWi026-B
(SF116 clone 2)
Donor's gene variants:
CFH
Donor diseases:
type 2 diabetes mellitus
age-related macular degeneration
UNEWi026-C
(SF116 clone K)
Donor's gene variants:
CFH
Donor diseases:
type 2 diabetes mellitus
age-related macular degeneration
STBCi110-A
(SFC116-03-01)
Donor's gene variants:
CFH
Donor diseases:
type 2 diabetes mellitus
age-related macular degeneration
UNEWi024-A
(F180-1)
Donor's gene variants:
CFH
Donor diseases:
age-related macular degeneration
UNEWi024-B
(F180-2)
Donor's gene variants:
CFH
Donor diseases:
age-related macular degeneration
UNEWi024-C
(F180-3)
Donor's gene variants:
CFH
Donor diseases:
age-related macular degeneration
UNEWi022-A
(F181 5.8)
Donor's gene variants:
CFH
Donor diseases:
age-related macular degeneration
UNEWi022-B
(F181 18.2)
Donor's gene variants:
CFH
Donor diseases:
age-related macular degeneration
UNEWi022-C
(F181 25.7)
Donor's gene variants:
CFH
Donor diseases:
age-related macular degeneration
SCTCi014-A-1
(IPS17-00056 Crispr clone O5)
Donor diseases:
Age-Related Macular Degeneration
SCTCi015-A-1
(IPS19-00051 Crispr clone H6)
Donor diseases:
Age-Related Macular Degeneration
CIRMi390-A
(CW70174)
Donor diseases:
type 2 diabetes mellitus
CIRMi391-A
(CW70175)
Donor diseases:
type 2 diabetes mellitus
CIRMi400-A
(CW70080)
Donor diseases:
type 2 diabetes mellitus
STBCi098-A
(SFC048-07-14)
Donor diseases:
type 2 diabetes mellitus
STBCi098-B
(SFC048-07-18)
Donor diseases:
type 2 diabetes mellitus
STBCi100-A
(SFC117-03-01)
Donor diseases:
type 2 diabetes mellitus
CIRMi434-A
(CW70230)
Donor diseases:
type 2 diabetes mellitus
STBCi107-A
(SFC104-03-01)
Donor diseases:
type 2 diabetes mellitus
STBCi098-C
(SFC048-07-17)
Donor diseases:
type 2 diabetes mellitus
SCTCi012-A
(IPS19-00027)
Donor diseases:
age-related macular degeneration
STBCi122-A
(SFC115-03-01)
Donor diseases:
type 2 diabetes mellitus
CIRMi452-A
(CW70255)
Donor diseases:
type 2 diabetes mellitus
SCTCi013-A
(IPS19-00053)
Donor diseases:
age-related macular degeneration
CIRMi454-A
(CW70257)
Donor diseases:
type 2 diabetes mellitus
STBCi126-A
(SFC105-03-01)
Donor diseases:
type 2 diabetes mellitus
STBCi127-A
(SFC107-03-01)
Donor diseases:
type 2 diabetes mellitus
Last update 27th January 2021
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator University of Newcastle (UNEW)
Owner Institute of Genetic Medicine
Distributors
Derivation country United Kingdom

External Databases

BioSamples SAMEA4567589
Cellosaurus CVCL_IT97
Wikidata Q54991226

General Information

Projects
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: allowed
Commercial use: allowed

Donor Information

General Donor Information

Sex male
Age of donor (at collection) 60-64

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
Sporadic typical T2D
Synonyms
  • NIDDM
  • non-insulin-dependent diabetes mellitus
  • type 2 diabetes
  • type II diabetes mellitus
  • insulin resistance
show more synonyms
Genetic variants
Donor is at high risk of developing age-related macular degeneration but has not been diagnosed with AMD at time of biopsy.
The donor is a carrier of a disease-associated mutation and not affected.
Synonyms
  • AMD
  • ARMD
  • Senile macular degeneration
  • Senile macular retinal degeneration
  • age related Maculopathies
  • age related maculopathy
  • age-related macular degeneration
  • macular degeneration, age-related
  • age related macular degeneration
show more synonyms
Genetic variants
CFH (target)
1q31.3
NM_000186.3:c.1204C>T
NP_000177.2:p.His402Tyr NC_000001.11:g.19669010
Homozygous
SCV000038294.5

Donor Relations

Other cell lines of this donor

External Databases (Donor)

BioSamples SAMEA4582266

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? No
Please provide contact information of the holder of the original Donor Information Sheet. Dr David Steel
Do you (Depositor/Provider) hold the original Donor Consent Form? No
If you do not hold the Donor Consent Form, do you know who does? No
Is there other documentation provided to the donor for consenting purposes? No
Confirm that consent was obtained by a qualified professional Yes
Has the donor been informed about how her/his data will be protected? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent expressly prevent the derivation of pluripotent stem cells? No
Does consent pertain to a specific research project? Yes
Details on restriction to research project Research use restricted to Retinal Degeneration and Dystrophies
Does consent permit unforeseen future research, without further consent? Yes
Does consent expressly prevent development of commercial products? No
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? No
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No

Does consent permit research by

an academic institution? Yes
a public organisation? Yes
a non-profit company? Yes
a for-profit corporation? Yes
Does consent expressly permit collection of genetic information? Yes
Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? Yes
How may genetic information associated with the cell line be accessed? Controlled Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? No
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? North East - Newcastle & North Tyneside 1 Research Ethics Committee
Approval number 11/NE/0294
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved? North East - Newcastle & North Tyneside 1 Research Ethics Committee
Approval number 11/NE/0294
Do you have obligations to third parties in regard to the use of the cell line? No
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation

General

Source cell type
Any skin fibroblast that is part of some dermis.
Source cell origin
Any portion of the organ that covers that body and consists of a layer of epidermis and a layer of dermis.
Synonyms
  • portion of skin
  • region of skin
  • skin
  • skin region
  • skin zone
show more synonyms
Age of donor (at collection) 60-64
Passage number reprogrammed P4

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Genes
Is reprogramming vector detectable?
No
Methods used
PCR

Vector free reprogramming

Other

Selection criteria for clones Based on morphology, growth rate and expression of SSEA4 and NANOG
Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 20 %
CO2 Concentration 5 %
Medium mTeSR™ 1

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
NANOG
Yes
SSEA-4
Yes
TRA 1-60
Yes
SSEA-1
No
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
Marker Expressed
Alpha FetoProtein
Yes
Mesoderm
Ont Id: UBERON_0000926
Marker Expressed
SMA
Yes
Ectoderm
Ont Id: UBERON_0000924
Marker Expressed
TUJ-1
Yes

Microbiology / Virus Screening

HIV 1 Negative
HIV 2 Negative
Hepatitis B Negative
Hepatitis C Negative
Mycoplasma Negative

Certificate of Analysis

Is there a certificate of analysis available?
Yes
Passage: P10

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
No clinically significant imbalance was detected
Passage number: P10
Karyotyping method: Molecular karyotyping by SNP array
http://

Other Genotyping (Cell Line)